Liothyronine

• UNSPSC Description:

  Liothyronine is an active form of thyroid hormone. Liothyronine binds to thyroid hormone receptors TRα and TRβ with Kis of 2.33 and 2.29 nM for hTRα and hTRβ, respectively. Liothyronine also binds to PVR and blocks the interaction of TIGIT/PVR[1][2][3].

• Target Antigen:

  Endogenous Metabolite; Thyroid Hormone Receptor

• Type:

  Natural Products

• Related Pathways:

  Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/3,3_acute_,5-Triiodo-L-thyronine.html

• Purity:

  99.82

• Solubility:

  1M NaOH : 50 mg/mL (ultrasonic;warming;heat to 60°C)|DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  OC1=C(C=C(C=C1)OC2=C(C=C(C=C2I)C[C@@H](C(O)=O)N)I)I

• Molecular Weight:

  650.97

• References & Citations:

  [1]Lin KH, et al. Stimulation of proliferation by 3,3',5-triiodo-L-thyronine in poorly differentiated human hepatocarcinoma cells overexpressing beta 1 thyroid hormone receptor. Cancer Lett. 1994 Oct 14;85(2):189-94.|[2]Bhat MK, et al. Conformational changes of human beta 1 thyroid hormone receptor induced by binding of 3,3',5-triiodo-L-thyronine. Biochem Biophys Res Commun. 1993 Aug 31;195(1):385-92.|[3]Hiroaki Shiohara, et al. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia. Bioorg Med Chem. 2012 Jun 1;20(11):3622-34.|[4]Zhou X, et al. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR. Cell Commun Signal. 2020 Sep 7;18(1):142. Acta Pharmacol Sin. 2024 May 24.|Adipocyte. 2022 Dec;11(1):84-98.|Am J Physiol Endocrinol Metab. 2024 Apr 3.|Cell Death Discov. 2022 Apr 30;8(1):236.|Cell Metab. 2023 Sep 7;S1550-4131(23)00304-2.|Cell Rep. 2024 Mar 18;43(3):113930.|Chem Eng J. 2024 Sep 15.|Eur J Med Chem. 2024 Mar 20:269:116344.|Food Science and Human Wellness. 2023 Nov;12(6);2061-2072.|J Med Chem. 2022 Jan 21.|J Nutr Biochem. 2020 Apr;78:108335.|J Therm Biol. 2024 Jul 2:123:103906.|Methods Mol Biol. 2023;2683:103-111.|Mol Metab. 2024 Oct 29:102053.|Nat Commun. 2023 Jun 2;14(1):3208.|Patent. US20220389379A1.|Sci Rep. 2024 Sep 2;14(1):20370.|bioRxiv. 2024 November 15.|J Ethnopharmacol. 2022 Aug 11;115622.|JCI Insight. 2021 Jun 22;6(12):142838.|Sci Adv. 2024 Feb 9;10(6):eadk3931.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Launched

• CAS Number:

  6893-02-3